Zydus Lifesciences signs pact with Synthon BV

Zydus Lifesciences has signed an exclusive development, licensing, supply and commercialisation pact with Synthon BV of the Netherlands for a novel oncology product for an undisclosed target. The novel 505(B)(2) oncology product is likely to be filed in 2026 and will offer additional strengths that are intended to provide reduced pill burden, flexibility for dose adjustment and enhanced patient compliance.

Under the terms of this agreement, Synthon will be responsible for the development, manufacturing and supply of the finished product. Zydus will be responsible for the NDA submission and commercialisation of the product in the US. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.